This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

16/100

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Down syndrome and Alzheimer's

Topic: Brain proteins, microglia and lab models

The anterior thalamic nuclei are important for cognition, and memory in particular. However, little is known about how the anterior thalamic nuclei are affected in many neurological disorders partly due to difficulties in selective segmentation in in vivo scans, due to their size and location. Post-mortem studies, therefore, remain a valuable source of information about the status of the anterior thalamic nuclei.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Perry, J. C., & Vann, S. D. (2024). Reduction in neurons immunoreactive for parvalbumin, calretinin and calbindin in the anteroventral thalamic nuclei of individuals with Down syndrome. bioRxiv. https://doi.org/10.1101/2024.02.01.578360

Vancouver

Perry JC, Vann SD. Reduction in neurons immunoreactive for parvalbumin, calretinin and calbindin in the anteroventral thalamic nuclei of individuals with Down syndrome. bioRxiv. 2024. doi:10.1101/2024.02.01.578360.

BibTeX

@article{perry2024-ed68acdf,
  author  = {Perry, J. C. and Vann, S. D.},
  title   = {{Reduction in neurons immunoreactive for parvalbumin, calretinin and calbindin in the anteroventral thalamic nuclei of individuals with Down syndrome}},
  journal = {bioRxiv},
  year    = {2024},
  doi     = {10.1101/2024.02.01.578360},
  url     = {https://doi.org/10.1101/2024.02.01.578360}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

However, little is known about how the anterior thalamic nuclei are affected in many neurological disorders partly due to difficulties in selective segmentation in in vivo scans, due to their size and location.
Post-mortem studies, therefore, remain a valuable source of information about the status of the anterior thalamic nuclei.
We used post-mortem tissue to assess the status of the anteroventral thalamic nucleus in Down syndrome using samples from males and females ranging from 22-65 years in age and comparing to tissue from age matched controls.
As expected, there was increased beta-amyloid plaque expression in the Down syndrome group.

Why it matters

This post-mortem study found fewer neurons expressing parvalbumin, calretinin and calbindin in the anteroventral thalamic nucleus of people with Down syndrome. It describes a change in brain tissue associated with Down syndrome but does not test any treatment, cure or prevention for Alzheimer's disease.

Study details

Evidence strengthLow

How this study scored 16/100

Preprint — not yet peer-reviewed. It scored 19 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 18 of the 94 points we could judge it on, which is 19 out of 100.

Component	Points	Why
Journal tier	2 / 10	Tier 4 — not a peer-reviewed journal (bioRxiv)
Journal's citation record	0 / 4	Not a journal article, so the journal's record does not count
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	4 / 10	Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 4 year(s) since 2024
Impact for its field and year	— / 6	No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Seralynne D. Vann: h-index 50 (OpenAlex, whole career)
Institution's track record	1 / 3	Cardiff University: institution h-index 1,251 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	18 / 94	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 18 of the 94 points we could judge it on is 19 out of 100.
Total	19 / 100	Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Down syndrome and Alzheimer's

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →